OBJECTIVE: To describe the later health status of newborn infants who received extracorporeal membrane oxygenation (ECMO) for acute respiratory failure in the era after the UK ECMO trial. DESIGN: Prospective follow up study of newborn infants who received ECMO at a single centre between January 1997 and January 2001. SETTING: Departments of ECMO and Paediatric Intensive Care, University Hospitals of Leicester. PATIENTS: All babies who received ECMO within 14 days of birth. INTERVENTIONS: Neurodevelopment screening using the schedule for growing skills-II (SGS-II) assessment tool. MAIN OUTCOME MEASURES: Survival at 12 months of age by disease and functional development at follow up. RESULTS: A total of 145 neonates received ECMO for treatment of respiratory failure. Of these, 108 (75%) were alive at 1 year of age. There were no deaths in children treated for respiratory failure secondary to meconium aspiration syndrome (73/145). Ninety three (86% of survivors) infants attended a follow up visit at 11-19 months postnatal age. Eighty two were classed as normal, seven as having "impairment", and four as having "severe disability". CONCLUSIONS: Most newborn infants with acute respiratory failure treated with ECMO will have a normal neurodevelopment screening assessment at 11-19 months of postnatal age. There is no evidence to suggest that changes in neonatal practice since the UK ECMO trial have led to changes in outcome of infants undergoing ECMO therapy.
OBJECTIVE: To describe the later health status of newborn infants who received extracorporeal membrane oxygenation (ECMO) for acute respiratory failure in the era after the UK ECMO trial. DESIGN: Prospective follow up study of newborn infants who received ECMO at a single centre between January 1997 and January 2001. SETTING: Departments of ECMO and Paediatric Intensive Care, University Hospitals of Leicester. PATIENTS: All babies who received ECMO within 14 days of birth. INTERVENTIONS: Neurodevelopment screening using the schedule for growing skills-II (SGS-II) assessment tool. MAIN OUTCOME MEASURES: Survival at 12 months of age by disease and functional development at follow up. RESULTS: A total of 145 neonates received ECMO for treatment of respiratory failure. Of these, 108 (75%) were alive at 1 year of age. There were no deaths in children treated for respiratory failure secondary to meconium aspiration syndrome (73/145). Ninety three (86% of survivors) infants attended a follow up visit at 11-19 months postnatal age. Eighty two were classed as normal, seven as having "impairment", and four as having "severe disability". CONCLUSIONS: Most newborn infants with acute respiratory failure treated with ECMO will have a normal neurodevelopment screening assessment at 11-19 months of postnatal age. There is no evidence to suggest that changes in neonatal practice since the UK ECMO trial have led to changes in outcome of infants undergoing ECMO therapy.
Authors: Marie Horan; Shingo Ichiba; Richard K Firmin; Hilliary M Killer; David Edwards; Denis Azzopardi; Rachel Hodge; Sailesh Kotecha; David Field Journal: J Pediatr Date: 2004-03 Impact factor: 4.406
Authors: G Ganesh Konduri; Alfonso Solimano; Gregory M Sokol; Joel Singer; Richard A Ehrenkranz; Nalini Singhal; Linda L Wright; Krisa Van Meurs; Eileen Stork; Haresh Kirpalani; Abraham Peliowski Journal: Pediatrics Date: 2004-03 Impact factor: 7.124
Authors: Brian W Gray; Jonathan W Haft; Jennifer C Hirsch; Gail M Annich; Ronald B Hirschl; Robert H Bartlett Journal: ASAIO J Date: 2015 Jan-Feb Impact factor: 2.872
Authors: Valentina Di Leo; Paolo Biban; Federico Mercolini; Francesco Martinolli; Andrea Pettenazzo; G Perilongo; Angela Amigoni Journal: Childs Nerv Syst Date: 2018-11-10 Impact factor: 1.475
Authors: Jeri S Burr; Tammara L Jenkins; Rick Harrison; Kathleen Meert; K J S Anand; John T Berger; Jerry Zimmerman; Joseph Carcillo; J Michael Dean; Christopher J L Newth; Douglas F Willson; Ronald C Sanders; Murray M Pollack; Eric Harvill; Carol E Nicholson Journal: Pediatr Crit Care Med Date: 2011-07 Impact factor: 3.624